Basic information
Biomarker: c-erbB-2
Biomarker subtype: gene
Clinical application: diagnosis
Histology type: endometrial carcinoma
Cohort characteristics
Country: China
Region: Harbin
Cohort age: 28;22
Protocol age: 19;16
Control age: 9;6
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 75 | EC | 40 | endometrial hyperplasia | 20 | NE | 15 |
Sample information
Sample type : tissue
Clinical method: RT-qPCR
Expression pattern : overexpresses
Disease information
Statictics: cutoff<60;cutoff>60
Cohort age: 28;22
Protocol age: 19;16
Control age: 9;6
Related information
Description: C-erbB-2 were correlated with the occurrence and the development of endometrial cancer, and thus can be used for the early diagnosis and prognosis of endometrial cancer. The present study laid the foundation for identifying new treatments for endometrial cancer.
Expression figure legend: Abscissa indicates pathological characteristics, the vertical axis represents gene content.$Reverse transcription quantitative polymerase chain reaction was used to determine the expression of MIF and c-erbB-2 mRNA in NE, endometrial hyperplasia and EC.
Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838132/figure/f3-mmr-13-05-3828/$https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838132/figure/f2-mmr-13-05-3828/
Approved symbol: ERBB2
Approved name: erb-b2 receptor tyrosine kinase 2
Locus type: gene with protein product
HGNC ID: HGNC:3430
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430
Symbol status: Approved
Previous symbols: NGL
Alias symbols: NEU HER-2 CD340 HER2 c-ERB2 c-ERB-2 MLN-19 p185(erbB2)
Alternative gene group name: MHA", "mHAg", "MiHA", "mHags", " minor H antigen | ErbB family| cluster of differentiation molecules", "cluster of designation molecules|
Subgroup: |Receptor tyrosine kinases| | MicroRNA host genes
OMIM: 164870
Omim link: https://www.omim.org/entry/164870
NCBI name: 2064
NCBI link: https://www.ncbi.nlm.nih.gov/gene/2064
Summary: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
Expression: Ubiquitous expression in kidney (RPKM 34.7), skin (RPKM 30.2) and 24 other tissues
NCBI gene expression https://www.ncbi.nlm.nih.gov/gene/2064#gene-expression
PDB ID: P04626
PDB link: https://www.ebi.ac.uk/pdbe/entry/search/index/?searchParams=%7B%22q_uniprot%22:%5B%7B%22value%22:%22(P04626)%22,%22condition1%22:%22AND%22,%22condition2%22:%22Contains%22%7D%5D,%22resultState%22:%7B%22tabIndex%22:0,%22paginationIndex%22:1,%22perPage%22:%2210%22,%22sortBy%22:%22Sort%20by%22%7D%7D
CC term ID: GO:0038143
CC term name: ERBB3:ERBB2 complex
Source description: REAC | MIRNA| CORUM
Term ID: REAC:R-HSA-9665233| REAC:R-HSA-9665245| REAC:R-HSA-9665244| REAC:R-HSA-9665247| REAC:R-HSA-9665246| REAC:R-HSA-9665251| REAC:R-HSA-9665250| REAC:R-HSA-1251932| REAC:R-HSA-1306955| REAC:R-HSA-9652282| REAC:R-HSA-9665737| REAC:R-HSA-9665230| REAC:R-HSA-9665249| MIRNA:hsa-miR-4790-5p| CORUM:6506| CORUM:7351
Term name: Resistance of ERBB2 KD mutants to trastuzumab | Resistance of ERBB2 KD mutants to tesevatinib| Resistance of ERBB2 KD mutants to sapitinib| Resistance of ERBB2 KD mutants to osimertinib| Resistance of ERBB2 KD mutants to neratinib| Resistance of ERBB2 KD mutants to lapatinib| Resistance of ERBB2 KD mutants to AEE788| PLCG1 events in ERBB2 signaling| GRB7 events in ERBB2 signaling| Drug-mediated inhibition of ERBB2 signaling| Drug resistance in ERBB2 TMD/JMD mutants| Drug resistance in ERBB2 KD mutants| Resistance of ERBB2 KD mutants to afatinib| hsa-miR-4790-5p| ERBB2-SPG1 complex| GDF15-ERBB2 complex
